• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

内源性 PPAR-α 激动剂油酰乙醇酰胺对非酒精性脂肪性肝病风险因素的影响:系统评价。

The effects of oleoylethanolamide, an endogenous PPAR-α agonist, on risk factors for NAFLD: A systematic review.

机构信息

Student Research Committee, Nutrition Research Center, School of Nutrition and Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.

Nutrition Research Center, Department of Clinical Nutrition, School of Nutrition and Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.

出版信息

Obes Rev. 2019 Jul;20(7):1057-1069. doi: 10.1111/obr.12853. Epub 2019 May 21.

DOI:10.1111/obr.12853
PMID:31111657
Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease. Recently, some novel compounds have been investigated for the prevention and treatment of NAFLD. Oleoylethanolamide (OEA), an endogenous PPAR-α agonist, has exhibited a plethora of pharmacological properties for the treatment of obesity and other obesity-associated metabolic complications. This systematic review was performed with a focus on the effects of OEA on the risk factors for NAFLD. PubMed, Scopus, Embase, ProQuest, and Google Scholar databases were searched up to December 2018 using relevant keywords. All articles written in English evaluating the effects of OEA on the risk factors for NAFLD were eligible for the review. The evidence reviewed in this article illustrates that OEA regulates multiple biological processes associated with NAFLD, including lipid metabolism, inflammation, oxidative stress, and energy homeostasis through different mechanisms. In summary, many beneficial effects of OEA have led to the understanding that OEA may be an effective therapeutic strategy for the management of NAFLD. Although a wide range of studies have demonstrated the most useful effects of OEA on NAFLD and the associated risk factors, further clinical trials, from both in vivo studies and in vitro experiments, are warranted to verify these outcomes.

摘要

非酒精性脂肪性肝病(NAFLD)是最常见的慢性肝病。最近,一些新型化合物已被用于预防和治疗 NAFLD。油酰乙醇酰胺(OEA)是一种内源性 PPAR-α 激动剂,具有治疗肥胖症和其他肥胖相关代谢并发症的多种药理学特性。本系统评价重点关注 OEA 对 NAFLD 危险因素的影响。使用相关关键词在 PubMed、Scopus、Embase、ProQuest 和 Google Scholar 数据库中搜索至 2018 年 12 月。所有评估 OEA 对 NAFLD 危险因素影响的英文文章均符合本综述的纳入标准。本文综述的证据表明,OEA 通过不同机制调节与 NAFLD 相关的多种生物学过程,包括脂质代谢、炎症、氧化应激和能量稳态。总之,OEA 的许多有益作用使人们认识到,OEA 可能是治疗 NAFLD 的有效治疗策略。尽管大量研究表明 OEA 对 NAFLD 和相关危险因素最有效,但仍需要进一步的临床研究,包括体内研究和体外实验,以验证这些结果。

相似文献

1
The effects of oleoylethanolamide, an endogenous PPAR-α agonist, on risk factors for NAFLD: A systematic review.内源性 PPAR-α 激动剂油酰乙醇酰胺对非酒精性脂肪性肝病风险因素的影响:系统评价。
Obes Rev. 2019 Jul;20(7):1057-1069. doi: 10.1111/obr.12853. Epub 2019 May 21.
2
A systematic review of the effects of oleoylethanolamide, a high-affinity endogenous ligand of PPAR-α, on the management and prevention of obesity.奥利诺酰胺(一种高亲和力的 PPAR-α 内源性配体)对肥胖的管理和预防作用的系统评价。
Clin Exp Pharmacol Physiol. 2020 Apr;47(4):543-552. doi: 10.1111/1440-1681.13238. Epub 2020 Jan 31.
3
Effect of oleoylethanolamide on diet-induced nonalcoholic fatty liver in rats.油酰乙醇胺对大鼠饮食诱导的非酒精性脂肪肝的影响。
J Pharmacol Sci. 2015 Mar;127(3):244-50. doi: 10.1016/j.jphs.2014.12.001. Epub 2014 Dec 9.
4
Oleoylethanolamide supplementation in obese patients newly diagnosed with non-alcoholic fatty liver disease: Effects on metabolic parameters, anthropometric indices, and expression of PPAR-α, UCP1, and UCP2 genes.奥利司他在新诊断为非酒精性脂肪性肝病的肥胖患者中的补充作用:对代谢参数、人体测量指数以及 PPAR-α、UCP1 和 UCP2 基因表达的影响。
Pharmacol Res. 2020 Jun;156:104770. doi: 10.1016/j.phrs.2020.104770. Epub 2020 Mar 23.
5
Oleoylethanolamide, an endogenous PPAR-alpha agonist, lowers body weight and hyperlipidemia in obese rats.油酰乙醇胺,一种内源性过氧化物酶体增殖物激活受体α(PPAR-α)激动剂,可降低肥胖大鼠的体重和高脂血症。
Neuropharmacology. 2005 Jun;48(8):1147-53. doi: 10.1016/j.neuropharm.2005.02.013. Epub 2005 Apr 21.
6
Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR-alpha).油酰乙醇胺通过激活核受体过氧化物酶体增殖物激活受体α(PPAR-α)来刺激脂肪分解。
J Biol Chem. 2004 Jul 2;279(27):27849-54. doi: 10.1074/jbc.M404087200. Epub 2004 Apr 26.
7
Expression of NF-κB, IL-6, and IL-10 genes, body composition, and hepatic fibrosis in obese patients with NAFLD-Combined effects of oleoylethanolamide supplementation and calorie restriction: A triple-blind randomized controlled clinical trial.肥胖非酒精性脂肪性肝病患者中 NF-κB、IL-6 和 IL-10 基因的表达、身体成分和肝纤维化:奥利诺酰胺补充和热量限制的联合作用:一项三盲随机对照临床试验。
J Cell Physiol. 2021 Jan;236(1):417-426. doi: 10.1002/jcp.29870. Epub 2020 Jun 22.
8
Oleoylethanolamide, an endogenous PPAR-α ligand, attenuates liver fibrosis targeting hepatic stellate cells.油酰乙醇胺,一种内源性过氧化物酶体增殖物激活受体-α(PPAR-α)配体,通过作用于肝星状细胞减轻肝纤维化。
Oncotarget. 2015 Dec 15;6(40):42530-40. doi: 10.18632/oncotarget.6466.
9
Oleoylethanolamide: The role of a bioactive lipid amide in modulating eating behaviour.油酰乙醇酰胺:一种生物活性脂质酰胺在调节摄食行为中的作用。
Obes Rev. 2018 Feb;19(2):178-197. doi: 10.1111/obr.12630. Epub 2017 Nov 10.
10
Analgesic properties of oleoylethanolamide (OEA) in visceral and inflammatory pain.油酰乙醇酰胺(OEA)在内脏痛和炎性疼痛中的镇痛特性。
Pain. 2007 Dec 15;133(1-3):99-110. doi: 10.1016/j.pain.2007.03.008. Epub 2007 Apr 20.

引用本文的文献

1
An olive oil-derived NAE mixture (Olaliamid) improves liver and cardiovascular health, and decreases meta-inflammation in naturally obese dogs: a double-blind, randomized, placebo-controlled study.一种源自橄榄油的NAE混合物(Olaliamid)可改善自然肥胖犬的肝脏和心血管健康,并减轻代谢性炎症:一项双盲、随机、安慰剂对照研究。
BMC Vet Res. 2025 Aug 6;21(1):505. doi: 10.1186/s12917-025-04946-y.
2
Oleoylethanolamide supplementation on cardiometabolic health: a systematic review and meta-analysis of randomized controlled trials.补充油酰乙醇胺对心脏代谢健康的影响:一项随机对照试验的系统评价和荟萃分析
Front Nutr. 2025 May 21;12:1553288. doi: 10.3389/fnut.2025.1553288. eCollection 2025.
3
Hepatoprotective and Antiatherosclerotic Effects of Oleoylethanolamide-Based Dietary Supplement in Dietary-Induced Obesity in Mice.
基于油酰乙醇胺的膳食补充剂对饮食诱导的小鼠肥胖的肝脏保护和抗动脉粥样硬化作用
Pathophysiology. 2025 Apr 18;32(2):16. doi: 10.3390/pathophysiology32020016.
4
Curcumin Analog J7 Attenuates Liver Fibrosis and Metabolic Dysregulation in a Rat Model of Type 2 Diabetes via Modulation of TGF-β/Smad and NF-κB/BCL-2/BAX Pathways.姜黄素类似物J7通过调节TGF-β/Smad和NF-κB/BCL-2/BAX信号通路减轻2型糖尿病大鼠模型的肝纤维化和代谢失调。
Drug Des Devel Ther. 2025 Apr 1;19:2411-2432. doi: 10.2147/DDDT.S511372. eCollection 2025.
5
Does myo-inositol supplementation influence oxidative stress biomarkers in patients with non-alcoholic fatty liver disease?补充肌醇是否会影响非酒精性脂肪性肝病患者的氧化应激生物标志物?
Food Sci Nutr. 2023 Dec 6;12(2):1279-1289. doi: 10.1002/fsn3.3842. eCollection 2024 Feb.
6
Effects of oleoylethanolamide supplementation on inflammatory biomarkers, oxidative stress and antioxidant parameters of obese patients with NAFLD on a calorie-restricted diet: A randomized controlled trial.补充油酰乙醇胺对热量限制饮食的非酒精性脂肪性肝病肥胖患者炎症生物标志物、氧化应激和抗氧化参数的影响:一项随机对照试验。
Front Pharmacol. 2023 Apr 7;14:1144550. doi: 10.3389/fphar.2023.1144550. eCollection 2023.
7
Improved glycemic status, insulin resistance and inflammation after receiving oral oleoylethanolamide supplement in people with prediabetes: a randomized controlled trial.糖尿病前期患者口服油酰乙醇胺补充剂后血糖状态、胰岛素抵抗及炎症改善:一项随机对照试验
Diabetol Metab Syndr. 2022 Jun 3;14(1):77. doi: 10.1186/s13098-022-00848-3.
8
Targeting the lysosome: Mechanisms and treatments for nonalcoholic fatty liver disease.靶向溶酶体:非酒精性脂肪性肝病的机制与治疗。
J Cell Biochem. 2022 Oct;123(10):1624-1633. doi: 10.1002/jcb.30274. Epub 2022 May 23.
9
Identification of oleoylethanolamide as an endogenous ligand for HIF-3α.鉴定油酰乙醇酰胺为 HIF-3α 的内源性配体。
Nat Commun. 2022 May 9;13(1):2529. doi: 10.1038/s41467-022-30338-z.
10
Integrative Hedonic and Homeostatic Food Intake Regulation by the Central Nervous System: Insights from Neuroimaging.中枢神经系统对享乐性和稳态性食物摄入的整合调节:神经影像学的见解
Brain Sci. 2022 Mar 24;12(4):431. doi: 10.3390/brainsci12040431.